Amarogentin (Secoiridoid glycoside)

Amarogentin is a bitter secoiridoid glycoside found primarily in Gentiana lutea (yellow gentian) root, notable for its exceptionally high bitterness index. It exerts metabolic and hepatoprotective effects largely by modulating GLUT4 glucose transporter expression in skeletal muscle and suppressing gluconeogenic enzymes such as PEPCK in the liver.

Origin & History

Amarogentin is a secoiridoid glycoside isolated from medicinal plants including Gentiana lutea, Swertia chirata, and Gentiana rigescens. This naturally occurring bitter terpenoid is obtained from these plant sources through standard phytochemical isolation techniques.

Historical & Cultural Context

Amarogentin is derived from plants traditionally used in medicine, particularly Gentiana lutea and Swertia chirata. While specific historical uses of the isolated compound are not documented, the source plants have been employed as bitter tonics for liver, metabolic, and digestive disorders.

Health Benefits

• May improve blood sugar control and insulin sensitivity by increasing skeletal muscle GLUT4 expression and reducing liver PEPCK (preliminary evidence from diabetic rat models)
• Shows potential for liver protection and anti-fibrotic effects at 100 mg/kg oral dose (preliminary evidence from CCl4-induced fibrosis in mice)
• May inhibit platelet aggregation and thrombus formation through PLCγ2-PKC-p47 cascade inhibition (preliminary evidence showing 9-18 mg/kg prolonged occlusion time in mice)
• Demonstrates anti-cancer stem cell activity by modulating Wnt and Hedgehog signaling pathways (preliminary in vitro evidence only)
• Exhibits antioxidant properties by upregulating SOD2, CAT, and GPx enzymes (preliminary evidence from yeast antiaging models)

How It Works

Amarogentin upregulates GLUT4 (glucose transporter type 4) expression in skeletal muscle tissue, enhancing insulin-stimulated glucose uptake and improving peripheral insulin sensitivity. It concurrently suppresses phosphoenolpyruvate carboxykinase (PEPCK), a rate-limiting enzyme in hepatic gluconeogenesis, thereby reducing fasting glucose output from the liver. In hepatoprotective contexts, amarogentin appears to attenuate TGF-β1-driven stellate cell activation and collagen deposition, contributing to its anti-fibrotic profile observed in CCl4-induced liver injury models.

Scientific Research

Current evidence for amarogentin is limited to preclinical animal and in vitro studies, with no human clinical trials identified. Key animal studies include diabetes models in rats (PMID: 27485449), liver fibrosis models in mice (PMID: 29112900), and thrombus formation models in mice (PMID: 24868545, 40849776).

Clinical Summary

Current evidence for amarogentin is confined to in vitro and animal studies, with no completed human clinical trials published as of early 2025. Diabetic rat models (streptozotocin-induced) have demonstrated improvements in fasting blood glucose and insulin sensitivity alongside measurable increases in skeletal muscle GLUT4 protein expression. Hepatoprotective effects, including reduced markers of fibrosis and liver enzyme normalization, were observed at an oral dose of 100 mg/kg in CCl4-injured rodents. The absence of human pharmacokinetic data, dose-ranging trials, and randomized controlled studies means all findings must be considered highly preliminary and not yet translatable to clinical recommendations.

Nutritional Profile

Amarogentin is a pure bioactive secoiridoid glycoside compound (C29H30O13, molecular weight 584.53 g/mol), not a whole food ingredient, and therefore has no meaningful macronutrient, micronutrient, vitamin, mineral, or fiber profile. It is a secondary metabolite found primarily in Swertia chirata (Indian gentian) and related Gentianaceae species, where it occurs at concentrations of approximately 0.05–3.5% dry weight depending on plant part and species. As an isolated compound, it is studied in pure or near-pure form (≥98% purity in research contexts). Key bioactive characteristics: it is one of the most bitter naturally occurring substances known (detectable at ~58 parts per billion). It consists of a glucose moiety linked to a secoiridoid aglycone (swertiamarin-related structure) esterified with three gallic acid units. Bioavailability is limited by its high molecular weight and glycosidic nature; intestinal and hepatic hydrolysis by β-glucosidases is required for partial aglycone release. Oral bioavailability in animal models is low to moderate, with significant first-pass metabolism. It is poorly water-soluble, which further constrains systemic absorption. No protein, fat, carbohydrate, or micronutrient content is applicable to this isolated compound. Typical experimental dosing in animal models ranges from 10–100 mg/kg body weight orally.

Preparation & Dosage

No human dosage data available. Animal studies used: 100 mg/kg orally for liver fibrosis in mice, 9-18 mg/kg orally for antithrombotic effects in mice, and 15-60 μM in vitro for platelet studies. All studies used purified compound rather than standardized extracts. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Milk thistle extract, berberine, alpha-lipoic acid, gymnema sylvestre, turmeric extract

Safety & Interactions

No formal human safety trials for isolated amarogentin have been published, making a comprehensive adverse effect profile impossible to establish at this time. As a potent bitter compound, high doses may cause gastrointestinal irritation, nausea, or increased gastric acid secretion, consistent with the broader gentian extract class. Theoretical pharmacodynamic interactions exist with antidiabetic medications (e.g., metformin, sulfonylureas, insulin) given its glucose-lowering mechanisms, potentially increasing hypoglycemia risk if combined. Amarogentin should be avoided during pregnancy and lactation due to the complete absence of safety data in these populations.